Therapeutic monoclonal antibodies at phase 3 clinical study for management of Covid-19

In late 2019, a new coronavirus called SARS-COV-2 triggered an epidemic in Wuhan, China, and now exists worldwide. SARS-COV2 is a highly contagious virus and is the cause of the current COVID19 pandemic. Covid19 can affect anyone, from mild to very severe. For some other illnesses caused by respiratory viruses (such as the flu), some people may become more severely ill because of characteristics such as old age or certain medical conditions that increase the risk of the disease. The purpose of this review study is to monitor the disease, field research, and factors that may contribute to the severity of the pathogen so that we can better understand why some people may have severe COVID19, which is one of the most important priorities. The CDC's strategy is to combat COVID19, which can provide critical information in decisions to protect the most vulnerable population. The review study was collected from articles indexed in Latin databases and reports from reputable health organizations from January to July 2020.